6-甲基-[1,2,4]噻唑并[1,5-b]吡嗪 | 114448-72-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并哒嗪类
• 中文名称: 6-甲基-[1,2,4]噻唑并[1,5-b]吡嗪
• 英文名称: 6-methyl[1,2,4]triazolo[1,5-b]pyridazine
• 英文别名: 6-Methyl-[1,2,4]triazolo[1,5-B]pyridazine
• CAS: 114448-72-5
• 化学式: C₆H₆N₄
• mdl: MFCD11044776
• 分子量: 134.14
• InChiKey: OBXPOYMOKBBFEN-UHFFFAOYSA-N

物化性质

• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1<br/>[FR] INHIBITEUR DE LA DÉMÉTHYLASE-1 SPÉCIFIQUE DE LA LYSINE
  申请人：QUANTICEL PHARMACEUTICALS INC

  公开号：WO2015089192A1

  公开（公告）日：2015-06-18

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本发明一般涉及治疗癌症和肿瘤性疾病的组合物和方法。本文提供了替代杂环衍生物化合物和包含该化合物的药物组合物。所述化合物和组合物对于抑制赖氨酸特异性去甲基化酶-1是有用的。此外，所述化合物和组合物对于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等是有用的。
• [EN] IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS<br/>[FR] DÉRIVÉS D'IMIDAZO[1,2-A]PYRIDINE ET DE [1,2,4]TRIAZOLO[1,5-A]PYRIDINE UTILES EN TANT QU'INHIBITEURS DE TLR9 POUR LE TRAITEMENT D'UNE FIBROSE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2022040259A1

  公开（公告）日：2022-02-24

  The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1, 5-a]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

  本发明涉及公式（I）的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶衍生物或其盐。本化合物是TLR9的抑制剂，可用于治疗、预防或减缓纤维化疾病，如肝纤维化、肾脏纤维化、胆管纤维化或胰腺纤维化、非酒精性脂肪性肝炎（NASH）、非酒精性脂肪肝病（NAFLD）、慢性肾脏病、糖尿病肾病、原发性硬化性胆管炎（PSC）或原发性胆汁性肝硬化（PBC）、或特发性肺纤维化（IPF）。
• Antibacterial compounds
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0216385A2

  公开（公告）日：1987-04-01

  A compound having the general formula wherein, R° is a hydrogen atom, a nitrogen-containing heterocyclic group, an acyl group or an amino-protective group; Z is S, S→0,0 or CH2; R4 is a hydrogen atom, a methoxy group, or a formamide group; R" is a hydrogen atom, a methyl group, a hydroxyl group, or a halogen atom; A is a condensed triazolio group which may be substituted, or a pharmaceutically acceptable salt or ester thereof is novel and has an excellent antibacterial activity.

  通式如下的化合物 其中，R° 是氢原子、含氮杂环基团、酰基或氨基保护基团；Z 是 S、S→0,0 或 CH2；R4 是氢原子、甲氧基或甲酰胺基团；R "是氢原子、甲基、羟基或卤素原子；A 是可被取代的缩合三唑基团，或其药学上可接受的盐或酯。
• 4-Azaindole compounds
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10730877B2

  公开（公告）日：2020-08-04

  Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

  公开了式 (I) 的化合物 其中 G、A、R1、R5 和 n 在本文中定义。还公开了使用此类化合物作为通过 Toll 样受体 7 或 8 或 9 发出信号的抑制剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗炎症和自身免疫性疾病。
• INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1
  申请人：Celgene Quanticel Research, Inc.

  公开号：EP3080100B1

  公开（公告）日：2022-11-30